scholarly journals Identification of Novel Prognostic Factors via Volumetric Analysis in Patients with Hepatocellular Carcinoma Treated With Liver Stereotactic Body Radiation Therapy

2017 ◽  
Vol 99 (2) ◽  
pp. E168-E169
Author(s):  
D. Long ◽  
F.M. Kong ◽  
J.O. Galle ◽  
M. Tann ◽  
W. Pi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Prognostic Factors ◽  
Stereotactic Body Radiation Therapy ◽  
Volumetric Analysis ◽  
Stereotactic Body Radiation

scholarly journals Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Changchen Jiang ◽  
Shenghua Jing ◽  
Han Zhou ◽  
Aomei Li ◽  
Xiangnan Qiu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Prognostic Factors ◽  
Stereotactic Body Radiation Therapy ◽  
Objective Response ◽  
Progression Free Survival ◽  
Stereotactic Body Radiation ◽  
Grade 3 ◽  
Arterial Chemoembolization

PurposeThis study aimed to evaluate the efficacy and safety of trans-arterial chemoembolization (TACE) followed by stereotactic body radiation therapy (SBRT) in treating Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) not amenable to resection and radiofrequency ablation (RFA).MethodsFrom February 2012 to January 2017, a total of 57 BCLC stage B HCC patients who were unsuitable candidates for resection and RFA treated with TACE combined with CyberKnife SBRT were included in this retrospective study. Patients underwent TACE for a median of two times (1–5 times) before SBRT. SBRT prescription doses ranged from 30 Gy to 50 Gy in 3–5 fractions.ResultsThe median follow-up time was 42 months. The objective response rate (CR + PR) was 85.9%, and the disease control rate (CR + PR + SD) was 96.5%. The local control (LC) rates were 91.1% and 84.3% at 1 and 2 years, respectively. The 1-, 2-, 3-year overall survival (OS) and the median survival time were 73.2%, 51.4%, 32.4% and 26.6 months, respectively. The 1-, 2-, and 3-year progression-free survival (PFS) were 34.2%, 21.6%, and 9%, respectively, with a median PFS time of 9.7 months. A subgroup analysis was conducted in 32 patients with AFP ≥ 200 ng/ml before TACE. OS was significantly prolonged in those with AFP that decreased by more than 75% than those with AFP that decreased by less than 75% (P = 0.018) after SBRT. The treatment was well tolerated with only one patient (1.8%) developed grade 3 gastrointestinal toxicity, and another patient developed non-classical RILD. In multivariate analysis, tumor length ≥ 10 cm and AFP ≥ 200 ng/ml were independent poor prognostic factors for OS.ConclusionThe combination of TACE and Cyberknife SBRT showed optimal efficacy with acceptable toxicity for BCLC stage B HCC.

scholarly journals Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e77472 ◽  
Author(s):  
Jean-Emmanuel Bibault ◽  
Sylvain Dewas ◽  
Claire Vautravers-Dewas ◽  
Antoine Hollebecque ◽  
Hajer Jarraya ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Prognostic Factors ◽  
Local Control ◽  
Stereotactic Body Radiation Therapy ◽  
Stereotactic Body Radiation

scholarly journals Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting

Liver Cancer ◽  
2017 ◽  
Vol 6 (4) ◽  
pp. 264-274 ◽  
Author(s):  
Zhao-Chong Zeng ◽  
Jinsil Seong ◽  
Sang Min Yoon ◽  
Jason Chia-Hsien Cheng ◽  
Ka-On Lam ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Liver Cancer ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Asia Pacific ◽  
Stereotactic Body Radiation ◽  
Expert Meeting
Sign in / Sign up

Export Citation Format

Share Document